Delving into the Latest Updates on BIOLAB SANUS Farmacêutica Ltda. with Synapse

Overview

Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours. Hyaluronic Acid promotes vaginal moisture, providing symptom relief in various situations such as:
* Vaginismus and other sexual dysfunctions related to penetration
* Users of hormonal contraceptives with lubrication loss
* Postpartum and lactational period
* Post antibacterial or antifungal therapies
* During systemic oncological treatments (chemotherapy, radiotherapy, hormone therapy)
* Climacteric (urogenital atrophy)
* Post urogynecological surgeries (correction of urinary incontinence, genital dystopias, etc.)
* Post vulvovaginal abrasive, chemical, laser, or high-frequency therapies
* Post cosmetic and genital rejuvenation therapies

Start Date01 Mar 2025

Sponsor / Collaborator

BIOLAB SANUS Farmacêutica Ltda.

NCT06085898 / Not yet recruitingNot Applicable

Assessment of Dermal Acceptance, Gynecological and pH Maintenance With Microbiological Analysis of Vaginal Secretion for Cosmetic Product

This is a single-centre, single-blind, non-comparative clinical trial to assess the safety of the investigational product through clinical probability assessment.
Thirty-three female participants, aged between 18-45, will be required. Assessment of dermal (dermatological) and gynecological acceptance, in addition to pH measurements and vaginal force collection for microbiological analysis at the beginning and end of the study.

Start Date05 Nov 2023

Sponsor / Collaborator

BIOLAB SANUS Farmacêutica Ltda.

[+1]

NCT04880889 / Not yet recruitingPhase 3

Study Phase III, Randomized, Double-dummy, Placebo Controlled, Single-center, of Regarding the Non-inferiority of the Medication BL3000, When Compared to Pantogar® Treatment of Telogen Effluvium in Women.

Study phase III, randomized, double-dummy, placebo controlled, single-center, of regarding the non-inferiority of the medication BL3000, when compared to Pantogar® treatment of telogen effluvium in women.
Research product: BL3000. Reference product: Pantogar® List of Study Center: MAIN INVESTIGATOR STUDY CENTER FONE Medcin Skin Institute Sérgio Schalka 11 36835357

Start Date01 Jan 2023

Sponsor / Collaborator

BIOLAB SANUS Farmacêutica Ltda.

100 Clinical Results associated with BIOLAB SANUS Farmacêutica Ltda.

Login to view more data

0 Patents (Medical) associated with BIOLAB SANUS Farmacêutica Ltda.

Login to view more data

1

Literatures (Medical) associated with BIOLAB SANUS Farmacêutica Ltda.

Animals

Is It Possible to Mitigate Fear of Fireworks in Dogs? A Study on the Behavioural and Physiological Effects of a Psychoactive Supplement

Article

Author: Georgetti, Barbara ; Dutra, Luisa M L ; Brito, Amanda C ; Ramos, Daniela ; Vasconcellos, Angélica S ; Leme, Fabiola O P ; Yazbek, Karina V B

Canine fear of fireworks is a common problem worldwide, with serious implications for the welfare of both dogs and their owners. Therapies for the problem are available, and herbal and nutraceutical agents are increasingly suggested by professionals; nonetheless, studies on their real efficacy in reducing firework fear are lacking. In a randomised, double-blinded, placebo-controlled study, 44 dogs (25 in the “supplement” group and 19 in the “placebo” group) completed a long-term continuous treatment with either a supplement made of tryptophan, valerian, and passiflora or a placebo, including two real exposures to fireworks (on 2020 Christmas and 2021 New Years’ Eve, after 42 and 48 days of treatment, respectively). Owners of both groups received the same general environmental management and food/toy offering recommendations for trying with their dogs on those nights. Behavioural (measured by LSSS—Lincoln Sound Sensitivity Scale and PANAS—Positive and Negative Activation scale, as rated by the owners) and stress (measured via salivary cortisol measures) reactions were evaluated. Significantly greater fear decrease (LSSS) was recorded in the “supplement” dogs, as compared to the “placebo” group. Cortisol dosages on New Year’s Eve (“noisy” night) were in line with behavioural results; “supplement” dogs showed a smaller increase in the stress response from 22:30 to 00:30 h on New Year’s Eve and a greater decrease in their stress response from 02:30 h to 10:30 h on New Year’s Day compared to “placebo” dogs. Smaller cortisol levels were also shown by “supplement” dogs than “placebo” dogs on a controlled “quiet night” (27th December). Owners’ rates on PANAS remained stable during the whole period of therapy for both groups. The evaluated supplement, a combination of tryptophan, valerian, and passiflora, showed satisfactory results and rare side effects when treating dogs fearful of fireworks.

100 Deals associated with BIOLAB SANUS Farmacêutica Ltda.

Login to view more data

100 Translational Medicine associated with BIOLAB SANUS Farmacêutica Ltda.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Dapaconazole ( CYP51A1 )	Tinea Pedis More	Discontinued
LOPAP (BIOLAB SANUS Farmacêutica Ltda.) ( thrombin )	Wounds and Injuries More	Pending
CNF021.03	Pain More	Pending
BL-122 ( PDE5A )	Mycoses More	Pending